Does the media refer more to INDV or JAZZ?

In the previous week, Jazz Pharmaceuticals had 35 more articles in the media than Indivior. MarketBeat recorded 42 mentions for Jazz Pharmaceuticals and 7 mentions for Indivior. Indivior's average media sentiment score of 1.54 beat Jazz Pharmaceuticals' score of 0.35 indicating that Indivior is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indivior 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Jazz Pharmaceuticals 11 Very Positive mention(s) 9 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor INDV or NBIX?

In the previous week, Neurocrine Biosciences had 16 more articles in the media than Indivior. MarketBeat recorded 23 mentions for Neurocrine Biosciences and 7 mentions for Indivior. Indivior's average media sentiment score of 1.54 beat Neurocrine Biosciences' score of 1.34 indicating that Indivior is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indivior 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Neurocrine Biosciences 20 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CORT or INDV?

In the previous week, Corcept Therapeutics had 17 more articles in the media than Indivior. MarketBeat recorded 24 mentions for Corcept Therapeutics and 7 mentions for Indivior. Indivior's average media sentiment score of 1.54 beat Corcept Therapeutics' score of 0.85 indicating that Indivior is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corcept Therapeutics 17 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Indivior 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to ELAN or INDV?

In the previous week, Elanco Animal Health had 7 more articles in the media than Indivior. MarketBeat recorded 14 mentions for Elanco Animal Health and 7 mentions for Indivior. Indivior's average media sentiment score of 1.54 beat Elanco Animal Health's score of 1.36 indicating that Indivior is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 12 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Indivior 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to AXSM or INDV?

In the previous week, Axsome Therapeutics had 25 more articles in the media than Indivior. MarketBeat recorded 32 mentions for Axsome Therapeutics and 7 mentions for Indivior. Indivior's average media sentiment score of 1.54 beat Axsome Therapeutics' score of 0.94 indicating that Indivior is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 19 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Indivior 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Indivior (INDV) Competitors

$34.87 -0.43 (-1.22%)

As of 08/28/2026 04:00 PM Eastern

Compare

INDV vs. JAZZ, NBIX, CORT, ELAN, and AXSM

Should you buy Indivior stock or one of its competitors? Indivior's main competitors and comparable companies include Jazz Pharmaceuticals (JAZZ), Neurocrine Biosciences (NBIX), Corcept Therapeutics (CORT), Elanco Animal Health (ELAN), and Axsome Therapeutics (AXSM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Indivior compare to Jazz Pharmaceuticals?

Indivior (NASDAQ:INDV) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, media sentiment, profitability and earnings.

Indivior has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, Jazz Pharmaceuticals has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market.

Indivior has higher earnings, but lower revenue than Jazz Pharmaceuticals. Indivior is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$1.24B	3.32	$210M	$2.79	12.50
Jazz Pharmaceuticals	$4.27B	3.72	-$356.15M	$14.50	16.86

60.3% of Indivior shares are held by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are held by institutional investors. 0.7% of Indivior shares are held by insiders. Comparatively, 4.1% of Jazz Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Jazz Pharmaceuticals had 35 more articles in the media than Indivior. MarketBeat recorded 42 mentions for Jazz Pharmaceuticals and 7 mentions for Indivior. Indivior's average media sentiment score of 1.54 beat Jazz Pharmaceuticals' score of 0.35 indicating that Indivior is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indivior	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Jazz Pharmaceuticals	11 Very Positive mention(s)	9 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Indivior presently has a consensus target price of $45.17, indicating a potential upside of 29.53%. Jazz Pharmaceuticals has a consensus target price of $285.44, indicating a potential upside of 16.73%. Given Indivior's higher possible upside, research analysts clearly believe Indivior is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	3.00

Indivior has a net margin of 26.65% compared to Jazz Pharmaceuticals' net margin of 20.45%. Jazz Pharmaceuticals' return on equity of 33.97% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indivior	26.65%	-283.11%	36.85%
Jazz Pharmaceuticals	20.45%	33.97%	13.02%

Summary

Jazz Pharmaceuticals beats Indivior on 11 of the 17 factors compared between the two stocks.

How does Indivior compare to Neurocrine Biosciences?

Indivior (NASDAQ:INDV) and Neurocrine Biosciences (NASDAQ:NBIX) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

60.3% of Indivior shares are owned by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are owned by institutional investors. 0.7% of Indivior shares are owned by insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Indivior has a net margin of 26.65% compared to Neurocrine Biosciences' net margin of 20.91%. Neurocrine Biosciences' return on equity of 22.43% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indivior	26.65%	-283.11%	36.85%
Neurocrine Biosciences	20.91%	22.43%	15.64%

Indivior currently has a consensus target price of $45.17, suggesting a potential upside of 29.53%. Neurocrine Biosciences has a consensus target price of $200.86, suggesting a potential upside of 30.38%. Given Neurocrine Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Neurocrine Biosciences is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Neurocrine Biosciences	0 Sell rating(s)	4 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.88

Indivior has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, Neurocrine Biosciences has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market.

In the previous week, Neurocrine Biosciences had 16 more articles in the media than Indivior. MarketBeat recorded 23 mentions for Neurocrine Biosciences and 7 mentions for Indivior. Indivior's average media sentiment score of 1.54 beat Neurocrine Biosciences' score of 1.34 indicating that Indivior is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indivior	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Neurocrine Biosciences	20 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Neurocrine Biosciences has higher revenue and earnings than Indivior. Indivior is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$1.24B	3.32	$210M	$2.79	12.50
Neurocrine Biosciences	$2.86B	5.47	$478.60M	$6.82	22.59

Summary

Neurocrine Biosciences beats Indivior on 13 of the 17 factors compared between the two stocks.

How does Indivior compare to Corcept Therapeutics?

Corcept Therapeutics (NASDAQ:CORT) and Indivior (NASDAQ:INDV) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

Corcept Therapeutics currently has a consensus target price of $138.17, suggesting a potential upside of 21.33%. Indivior has a consensus target price of $45.17, suggesting a potential upside of 29.53%. Given Indivior's stronger consensus rating and higher possible upside, analysts plainly believe Indivior is more favorable than Corcept Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corcept Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Indivior	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

Indivior has a net margin of 26.65% compared to Corcept Therapeutics' net margin of 6.52%. Corcept Therapeutics' return on equity of 8.26% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corcept Therapeutics	6.52%	8.26%	6.45%
Indivior	26.65%	-283.11%	36.85%

Corcept Therapeutics has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market. Comparatively, Indivior has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market.

In the previous week, Corcept Therapeutics had 17 more articles in the media than Indivior. MarketBeat recorded 24 mentions for Corcept Therapeutics and 7 mentions for Indivior. Indivior's average media sentiment score of 1.54 beat Corcept Therapeutics' score of 0.85 indicating that Indivior is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corcept Therapeutics	17 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Indivior	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

93.6% of Corcept Therapeutics shares are held by institutional investors. Comparatively, 60.3% of Indivior shares are held by institutional investors. 20.7% of Corcept Therapeutics shares are held by company insiders. Comparatively, 0.7% of Indivior shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Indivior has higher revenue and earnings than Corcept Therapeutics. Indivior is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corcept Therapeutics	$761.41M	16.17	$99.65M	$0.42	271.14
Indivior	$1.24B	3.32	$210M	$2.79	12.50

Summary

Indivior beats Corcept Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Indivior compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Indivior (NASDAQ:INDV) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

Indivior has lower revenue, but higher earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$5.02B	2.40	-$232M	-$0.41	N/A
Indivior	$1.24B	3.32	$210M	$2.79	12.50

Elanco Animal Health currently has a consensus target price of $29.09, suggesting a potential upside of 20.41%. Indivior has a consensus target price of $45.17, suggesting a potential upside of 29.53%. Given Indivior's higher probable upside, analysts clearly believe Indivior is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Indivior	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

Indivior has a net margin of 26.65% compared to Elanco Animal Health's net margin of -3.96%. Elanco Animal Health's return on equity of 8.13% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-3.96%	8.13%	3.99%
Indivior	26.65%	-283.11%	36.85%

In the previous week, Elanco Animal Health had 7 more articles in the media than Indivior. MarketBeat recorded 14 mentions for Elanco Animal Health and 7 mentions for Indivior. Indivior's average media sentiment score of 1.54 beat Elanco Animal Health's score of 1.36 indicating that Indivior is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	12 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Indivior	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

97.5% of Elanco Animal Health shares are held by institutional investors. Comparatively, 60.3% of Indivior shares are held by institutional investors. 1.1% of Elanco Animal Health shares are held by company insiders. Comparatively, 0.7% of Indivior shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Elanco Animal Health has a beta of 1.67, indicating that its share price is 67% more volatile than the broader market. Comparatively, Indivior has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market.

Summary

Elanco Animal Health beats Indivior on 9 of the 17 factors compared between the two stocks.

How does Indivior compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Indivior (NASDAQ:INDV) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings, dividends and media sentiment.

Indivior has a net margin of 26.65% compared to Axsome Therapeutics' net margin of -24.68%. Axsome Therapeutics' return on equity of -265.55% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-24.68%	-265.55%	-28.10%
Indivior	26.65%	-283.11%	36.85%

81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 60.3% of Indivior shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by insiders. Comparatively, 0.7% of Indivior shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Indivior has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$776.57M	13.42	-$183.17M	-$3.75	N/A
Indivior	$1.24B	3.32	$210M	$2.79	12.50

Axsome Therapeutics currently has a consensus target price of $267.60, indicating a potential upside of 34.46%. Indivior has a consensus target price of $45.17, indicating a potential upside of 29.53%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Axsome Therapeutics is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91
Indivior	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Axsome Therapeutics had 25 more articles in the media than Indivior. MarketBeat recorded 32 mentions for Axsome Therapeutics and 7 mentions for Indivior. Indivior's average media sentiment score of 1.54 beat Axsome Therapeutics' score of 0.94 indicating that Indivior is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	19 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Indivior	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Axsome Therapeutics has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market. Comparatively, Indivior has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market.

Summary

Axsome Therapeutics beats Indivior on 9 of the 17 factors compared between the two stocks.

Get Indivior News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INDV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INDV vs. The Competition

Export

Metric	Indivior	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.12B	$12.15B	$7.20B	$12.90B
Dividend Yield	N/A	2.62%	2.54%	11.28%
P/E Ratio	12.50	787.65	273.16	25.45
Price / Sales	3.32	792.39	592.64	73.57
Price / Cash	12.82	91.95	76.74	53.00
Price / Book	-19.81	11.97	12.98	6.14
Net Income	$210M	$2.83B	$3.48B	$348.86M
7 Day Performance	-5.42%	0.39%	0.13%	-0.80%
1 Month Performance	-13.30%	5.34%	7.08%	4.13%
1 Year Performance	43.62%	6.05%	24.67%	15.17%

Indivior Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INDV Indivior	4.4053 of 5 stars	$34.87 -1.2%	$45.17 +29.5%	+43.6%	$4.12B	$1.24B	12.50	1,051	News Coverage Positive News
JAZZ Jazz Pharmaceuticals	4.1514 of 5 stars	$257.71 +1.3%	$272.89 +5.9%	+91.4%	$16.55B	$4.60B	17.58	2,890	Trending News Analyst Forecast Analyst Revision
NBIX Neurocrine Biosciences	4.9549 of 5 stars	$152.51 -0.3%	$200.86 +31.7%	+10.4%	$15.47B	$3.37B	22.31	2,000	News Coverage Positive News Analyst Upgrade
CORT Corcept Therapeutics	4.0611 of 5 stars	$124.32 +0.9%	$138.17 +11.1%	+63.3%	$13.39B	$761.41M	294.87	300	News Coverage Insider Trade
ELAN Elanco Animal Health	4.6997 of 5 stars	$24.71 +1.2%	$29.09 +17.7%	+31.5%	$12.36B	$4.72B	N/A	9,400	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INDV) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Indivior (INDV) Competitors

INDV vs. JAZZ, NBIX, CORT, ELAN, and AXSM

How does Indivior compare to Jazz Pharmaceuticals?

Summary

How does Indivior compare to Neurocrine Biosciences?

Summary

How does Indivior compare to Corcept Therapeutics?

Summary

How does Indivior compare to Elanco Animal Health?

Summary

How does Indivior compare to Axsome Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INDV vs. The Competition

Indivior Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Indivior (INDV) Competitors

INDV vs. JAZZ, NBIX, CORT, ELAN, and AXSM

How does Indivior compare to Jazz Pharmaceuticals?

Which has more volatility & risk, INDV or JAZZ?

Which has stronger valuation & earnings, INDV or JAZZ?

Do insiders and institutionals have more ownership in INDV or JAZZ?

Does the media refer more to INDV or JAZZ?

Do analysts rate INDV or JAZZ?

Is INDV or JAZZ more profitable?

Summary

How does Indivior compare to Neurocrine Biosciences?

Do institutionals & insiders have more ownership in INDV or NBIX?

Is INDV or NBIX more profitable?

Do analysts prefer INDV or NBIX?

Which has more volatility and risk, INDV or NBIX?

Does the media favor INDV or NBIX?

Which has preferable earnings and valuation, INDV or NBIX?

Summary

How does Indivior compare to Corcept Therapeutics?

Do analysts recommend CORT or INDV?

Is CORT or INDV more profitable?

Which has more risk & volatility, CORT or INDV?

Does the media prefer CORT or INDV?

Do institutionals and insiders hold more shares of CORT or INDV?

Which has better valuation & earnings, CORT or INDV?

Summary

How does Indivior compare to Elanco Animal Health?

Which has preferable earnings & valuation, ELAN or INDV?

Do analysts rate ELAN or INDV?

Is ELAN or INDV more profitable?

Does the media refer more to ELAN or INDV?

Do insiders & institutionals have more ownership in ELAN or INDV?

Which has more volatility & risk, ELAN or INDV?

Summary

How does Indivior compare to Axsome Therapeutics?

Is AXSM or INDV more profitable?

Do institutionals & insiders have more ownership in AXSM or INDV?

Which has higher earnings & valuation, AXSM or INDV?

Do analysts rate AXSM or INDV?

Does the media refer more to AXSM or INDV?

Which has more volatility and risk, AXSM or INDV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INDV vs. The Competition

Indivior Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools